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We describe here an innovative, non-transgenic animal model of Alzheimer’s disease. This model mimics early stages of
sporadic disease, which represents the vast majority of cases. The model was obtained by interfering with the complex between
a disintegrin and metalloproteinase domain containing protein 10 (ADAM10), the main a-secretase candidate, and its partner,
synapse-associated protein 97, a protein of the postsynaptic density-membrane associated guanylate kinase family. Association
of ADAM10 with synapse-associated protein 97 governs enzyme trafficking and activity at synapses. Interfering with the
ADAM10/synapse-associated protein 97 complex for 2 weeks by means of a cell-permeable peptide strategy is sufficient to
shift the metabolism of the amyloid precursor protein towards amyloidogenesis and allows the reproduction of initial phases of
sporadic Alzheimer’s disease. After 2 weeks of treatment, we detected progressive Alzheimer’s disease-like neuropathology,
with an increase of b-amyloid aggregate production and of tau hyperphosphorylation, and a selective alteration of N-methyl-D-
aspartic acid receptor subunit composition in the postsynaptic compartment of mouse brain. Behavioural and electrophysio-
logical deficits were also induced by peptide treatment.
Keywords: animal models; SAP97; NMDA; synaptopathy; amyloid precursor protein metabolism
Abbreviations: ADAM10 = a disintegrin and metalloproteinase domain with protein 10; Ab=b-amyloid peptide; Ala = Tat-Ala
ADAM10709-729 peptide; CTF = carboxy terminal fragment; Pro = Tat-Pro ADAM10709-729 peptide; SAP97 = synapse-associated
protein 97; TIF = Triton-X insoluble fraction
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Alzheimer’s disease is the most common cause of dementia and
no cure is available at the moment. The underlying neuropathol-
ogy of Alzheimer’s disease includes extracellular deposition of
b-amyloid peptide (Ab), intraneuronal accumulation of aberrant
forms of hyperphosphorylated tau (Selkoe, 2001) as well as syn-
apse dysfunction and neuronal loss (DeKosky and Scheff, 1990;
Selkoe, 2002).
Substantial data indicate accumulation of Ab in the brain, par-
ticularly in its non-fibrillar soluble oligomeric forms, as the primary
influence driving Alzheimer’s disease pathogenesis (Hardy and
Higgins, 1992). The rest of the disease process, including forma-
tion of neurofibrillary tangles and synapse loss, is considered a
downstream consequence of Ab deposition and it is proposed to
result from an imbalance between Ab production and Ab clear-
ance. Ab derives from the concerted action of b–secretase (Vassar
et al., 1999), which mediates amyloid precursor protein shedding
at Ab N-terminus and g-secretase, responsible for amyloid precur-
sor protein C-terminal stub cleavage (De Strooper et al., 1998).
Alternatively, amyloid precursor protein processing is exerted by a
disintegrin and metalloproteinase (ADAM10) family member that
prevents Ab formation (Lammich et al., 1999; Postina et al.,
2004).
The generation of animal models that recapitulate characteristic
features of Alzheimer’s disease is of great relevance to improve
the understanding of disease pathogenesis and to develop new
therapies. Current models of Alzheimer’s disease rely on informa-
tion gathered from inherited familiar forms. Identification in vari-
ous human pedigrees of gene mutations in amyloid precursor
protein (Goate et al., 1991), in presenilin-1 and -2 (Scheuner
et al., 1996) provided a potential tool of generating rodent
models of the disease. Despite their undoubted value, transgenic
Alzheimer’s disease mice show a number of pitfalls, i.e. they fail to
model the progressive stages of the disease, which questions their
role as pre-clinical models of Alzheimer’s disease. There is no
mouse line that models aetiology of late-onset/age-related spor-
adic Alzheimer’s disease, which accounts for the vast majority of
cases. Thus, focusing on new hypotheses concerning Alzheimer’s
disease pathogenesis and on the corresponding modelling is now a
need.
Recently, Kim and colleagues reported two potentially patho-
genic mutations with incomplete penetrance for late-onset familial
Alzheimer’s disease in the region encoding the prodomain
sequence in the gene for ADAM10 (Kim et al., 2009). ADAM10
interacts directly with synapse-associated protein (SAP) 97, a
cargo protein of the postsynaptic density-membrane associated
guanylate kinase (PSD-MAGUK) family (Marcello et al., 2007).
Since SAP97 is involved in the trafficking of molecules to the
glutamatergic synapse (Leonard et al., 1998; Sans et al., 2001)
and in events controlling synaptic transmission, its role in neuro-
degenerative diseases has been largely addressed and alterations
have been identified in early stages of several disorders (Nash
et al., 2005; Lau and Zukin, 2007). The direct binding of
proline-rich domains of the tail of ADAM10 to the SH3 domain
of SAP97 promotes ADAM10 trafficking to synaptic membranes
and regulates enzyme activity on amyloid precursor protein in pri-
mary neuronal cultures and, acutely, in rodent brains (Marcello
et al., 2007). Therefore, interfering with ADAM10/SAP97 com-
plex appears as an ideal approach to investigate the connection
between amyloid precursor protein metabolism and synaptic dys-
function in early phases of Alzheimer’s disease.
Here, we describe the generation of an innovative mouse model
of Alzheimer’s disease through uncoupling of ADAM10 from
SAP97. Disruption of the ADAM10/SAP97 complex is sufficient
to reduce ADAM10 levels at synaptic sites as well as to decrease
its activity, thus shifting amyloid precursor protein metabolism to-




Hippocampi from six patients with Alzheimer’s disease and six healthy
controls were obtained from The Netherland Brain Bank. Established
Braak and Braak criteria were used to categorize Alzheimer’s disease
tissues (Braak and Braak, 1991). Healthy controls had no history of
psychiatric or neurological disease and no evidence of age-related
neurodegeneration. All procedures were in accordance with the
National Institutes of Health Guide for Care and Use of laboratory
human tissues and were approved by the Ethics Committee of the
University of Milan.
Animal treatment
Adult male C57BL/6 mice, 8 weeks old, were treated with the cell-
permeable peptide Tat-Pro ADAM10709-729 (Pro, NH2-YGRKKRR
QRRRPKLPPPKPLPGTLKRRRPPQP-COOH), obtained by linking the
11 amino acid human immunodeficiency virus Tat transporter to a
21 amino acid sequence corresponding to the ADAM10 proline-rich
domains, or with Tat-Ala ADAM10709-729 (Ala, NH2-YGRKKRRQRRRA
KLAAAKALAGTLKRRRAAQA-COOH) (Xigenpharma, Lausanne, CH).
Peptides were conjugated to fluorescein. Peptides were administered
subcutaneously for 7 or 14 days through osmotic minipumps
(Alzet2002, Charles River, Calco, LC, Italy) or injected intraperitoneally
for 1 day. Dose regimens corresponded to 1 nmol/g. Animals were
killed 1, 7 or 14 days after treatment and the brain was rapidly dis-
sected. Four independent experiments with the two groups, Ala and
Pro (three animals per group) were performed for biochemical experi-
ments. Animal handling and surgical procedures were carried out with
care taken to minimize discomfort and pain in accordance with ethical
regulations and guidelines of the European Communities Council
(Directive of 14 November 1986, 86/609/EEC).
Sample preparation
Triton-X insoluble fraction (TIF) and soluble fraction S2 were obtained
as previously described (Gardoni et al., 2001; Marcello et al., 2007).
Sodium dodecyl sulphate
polyacrylamide gel electrophoresis
Samples (homogenate and TIF) were separated by electrophoresis on
a 7% sodium dodecyl sulphate polyacrylamide gel electrophoresis
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(SDS–PAGE) gel, while the S2 fraction was separated on a 6% SDS–
PAGE gel. To detect amyloid precursor protein carboxy terminal frag-
ments (CTFs), Tris–Tricine gels at 15% were used. Proteins were
transferred to a nitrocellulose membrane and probed with the corres-
ponding primary antibody followed by incubation with appropriate
horseradish peroxidase-conjugated secondary antibodies (Pierce,
Rockford, IL, USA).
Immunohistochemistry
Mice were deeply anaesthetized with tribromoethanol (intraperitone-
ally, 1 mg/kg) and perfused through the ascending aorta with physio-
logical saline followed by fixative solution (4% paraformaldehyde in
0.1 M phosphate buffer, pH 7.4). Brains were removed and post-fixed
overnight at 4C in the same fixative. Series of 50 mm thick coronal
sections were cut using a vibratome. For Congo Red staining, slices
were washed in water, incubated in 1% Congo Red solution and then
differentiated in alkaline alcohol (0.2% KOH in 80% ethanol) and
counterstained with haematoxylin. For tau phosphorylation immuno-
staining, sections were washed in phosphate-buffered saline, treated
with 2% H2O2 in phosphate-buffered saline and incubated in
5% normal goat serum in phosphate-buffered saline containing
0.5% Triton X-100. Sections were incubated with anti-tau AT8 anti-
body at a concentration of 5 mg/ml, overnight at 4C. Biotinylated
goat-anti-mouse IgG (Vector, Burlingame, CA, USA) was applied at
a dilution of 1:500, followed by incubation with streptavidin-
conjugated horseradish peroxidase (Vector) for 1 h. Tissue-bound per-
oxidase was detected using 3,3-diamino-benzidine (0.025%) as a
chromogen. Immunoreacted sections were placed on microscope
slides and coverslipped with mounting medium.
Immunoprecipitation
Fifty mg of (for ADAM10/SAP97, Akap79/150/SAP97, GluR1/SAP97
and PYK-2/PSD-95 immunoprecipitation) or 70 mg (for SAP97/NR2A
immunoprecipitation) of homogenate from mice treated with Ala or
Pro were incubated overnight with an antibody against ADAM10,
Akap79/150, GluR1, PYK2 or SAP97. Co-immunoprecipitation was
carried out as previously described (Marcello et al., 2007).
Determination of Ab release
For evaluation of Ab release from mice treated with Ala or Pro, an
enzyme-linked immunosorbent assay kit was used (IBL, Gunma,
Japan). The test was performed on total homogenate following the
manufacturer’s instructions. A standard curve ranging from 0 to
800 pg/ml was obtained with each point corresponding to the average
of two measurements.
Quantification and statistical analysis
Quantification of western blot analysis was performed by computer-
assisted imaging (Quantity-One System, BioRad, Hercules, CA, USA)
and statistical evaluations were performed according to two-tailed
paired Student’s t-test or one-way ANOVA followed by appropriate
post hoc tests. Quantification of immunostaining is shown as fold
difference compared with controls (healthy controls or Ala) in the
same experiment. Values are means  SEM for four independent
experiments for a total of 24 animals.
Hippocampal slice preparation and
electrophysiology
Fourteen days after surgical minipump insertion, mice were decapi-
tated without anaesthesia. Hippocampi were quickly dissected out
in ice-cold oxygenated artificial CSF containing the following
(in mM): 120 NaCl, 2.5 KCl, 2.5 CaCl2, 1.2 MgCl2, 26.2 NaHCO3,
1.0 NaH2PO4 and 11.0 glucose, bubbled with a mixture of
95% O2/5% CO2, pH 7.4. Transverse hippocampal slices (400 mm;
n= 8 slices from n= 3 mice per group) were cut and maintained in a
humidified holding chamber at room temperature for 1 h for recovery.
Individual slices were transferred to an interface recording chamber
(Fine Science Tools, Foster City, CA, USA) where they were continu-
ously perfused with artificial CSF maintained at 29C, at a flow rate of
1.5–2 ml/min. Extracellular field excitatory postsynaptic potentials were
recorded in the stratum radiatum of area CA1 of the hippocampus
using glass electrodes filled with 3 M NaCl coupled to the input
stage of a Warner IE-210 amplifier (Handen, CT, USA). Stimuli were
delivered to the commissural/Schaffer collateral afferents at 0.033 Hz
(0.1 ms pulse duration) with a concentric bipolar stainless steel elec-
trode. Data were collected and analysed online (10 kHz sampling rate)
using pClamp software (Clampex, Axon Instruments, CA, USA). A
stimulus intensity that elicited an extracellular field excitatory
postsynaptic potential amplitude that was 33% of the maximum
was used. Long-term potentiation was induced by a high-frequency
stimulation, consisting of four trains of 100 Hz for 1 s, separated by
30 s. Synaptic activity was measured as the maximal slope of the rising
phase of the extracellular field excitatory postsynaptic potential. Each
experiment was normalized to the mean value of the extracellular field
excitatory postsynaptic potential slope recorded during the baseline
(20 min of stable recording before high-frequency stimulation).
Long-term potentiation values were calculated as the percentage in-
crease in the extracellular field excitatory postsynaptic potential slope
50–60 min after the end of high-frequency stimulation compared with
the baseline value. Data are presented as means  SEM, and ANOVA
was used for statistical analysis.
Novel object recognition
Twelve days after surgical minipump insertion, mice treated with Ala
and Pro (n= 9 per group) were habituated to the test arena for 5 min
in the absence of any object. In the first trial, the mice were presented
for 10 min with two objects of identical size and shape. In the second
trial, the mice were presented for 10 min with a duplicate of one of
the objects from the first trial and a new object differing in shape.
During both trials, exploration of the object was defined as the time
spent sniffing, licking or touching the object. The discrimination index
[novel (t)  familiar (t)]/[total time (t) at novel + familiar], number of
total movements in 5 min and time (s) spent investigating in 10 min
were evaluated. Results are shown as mean SEM, and ANOVA fol-
lowed by Fisher as a post hoc test were used for statistical analysis.
DyOlistic labelling
Fourteen days after surgical minipump insertion, mice treated with
cell-permeable peptides Pro and Ala (n= 6 per group) were anaesthe-
tized and perfused with paraformaldehyde. Transverse hippocampal
CA1 apical and cortical layer I slices (300 mm) were cut with a vibra-
tome and slices were kept in phosphate buffer. Tungsten particles
were coated with a lipophilic dye, DiI (Molecular Probes, Eugene,
OR, USA). Microcarriers were loaded into the gene gun and then
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fired into tissue slices with the BioRad Gene Gun with a gas pressure
200 psi at a distance of 40 mm. Slices were kept for 10 min in 0.1 M
phosphate buffer and then for 2 h in 4% paraformaldehyde. After
24 h, images of DiI-labelled structures in hippocampal CA1 stratum
radiatum and layer I of the somatosensory cortex were acquired
using the Zeiss Confocal LSM510 microscope with 63 objective. At
least 10 z-stack images were acquired for each animal and for each
area of interest. The ImageJ software program was used to quantify
DiI-labelled neurons. Dendritic segments were chosen randomly and
were at least one soma’s length away from the cell soma. Four par-
ameters were measured, including spine density, spine area, spine
length and spine head diameter. All measurements were made with
the investigator blinded to the treatment used. Results are shown as
means of n= 33 neurons  SEM (at least 10 spines were measured for
each neuron) and Student’s t-test was used for statistical analysis.
Antibodies
The following antibodies were used: polyclonal antibody anti-ADAM10
and polyclonal antibody AB2072 against amyloid precursor protein
from Abcam (Cambridge, MA, USA); monoclonal antibody anti-
GluR1, monoclonal antibody anti-PYK-2 and monoclonal antibody
anti--CaMKII from Millipore (Billerica, MA, USA); monoclonal anti-
body anti-SAP97 from Stressgen (Ann Arbor, MI, USA). Polyclonal
antibody anti-Actin, monoclonal antibody anti-Tubulin and monoclonal
antibody anti-NR2A from Sigma (St Louis, MO, USA); monoclonal
antibody AT8 against tau from Pierce; monoclonal antibody
anti-GluR2 and monoclonal antibody anti-PSD-95 from Neuromab
(Davis, CA, USA); monoclonal antibody anti-NR1 and polyclonal
antibody anti-NR2B from Invitrogen (Carlsbad, CA, USA); polyclonal
antibody anti-AKAP79/150 from Santa Cruz Biotechology (Santa
Cruz, CA, USA); and monoclonal antibody anti-N-Cadherin from BD
Bioscience (Sparks, MD, USA).
Results
ADAM10/SAP97 association is reduced
in mice after 2 weeks of treatment with
Pro peptide and in Alzheimer’s disease
patients at Braak level 4
Interfering acutely with the ADAM10/SAP97 complex inhibits
ADAM10 trafficking to the postsynaptic membrane and its activity
in rodents (Marcello et al., 2007).
On the basis of this observation, we supposed that subchronic
disruption of the ADAM10/SAP97 complex could mimic one of
the events occurring in sporadic Alzheimer’s disease and could
allow the generation of a model of Alzheimer’s disease.
To investigate this, Tat-Pro ADAM10709–729 peptide (Pro)
(Marcello et al., 2007) was used, in which ADAM10 proline-rich
domains (amino acids 709–729), responsible for binding to SAP97,
are fused to the Tat transporter sequence (Aarts et al., 2002;
Fig. 1A). Eight-week-old mice were exposed subcutaneously for
2 weeks to the Pro peptide. As a control, we used an inactive
peptide, Tat-Ala ADAM10709-729 (Ala), where all prolines were
substituted by alanines.
To validate our tool, peptide penetration into neurons was con-
firmed by double staining with an anti-Tat antibody, used to visu-
alize peptides, and an anti-MAP-2 antibody, used as a neuronal
marker (Supplementary Fig. 1). Peptide capability to interfere with
the association between SAP97 and ADAM10 was investigated by
co-immunoprecipitation experiments from total brain homogen-
ates. A reduction of the ADAM10/SAP97 immunocomplex was
observed in mice treated with Pro compared with Ala (Fig. 1B;
n= 4, P= 0.005, 41.3 6.5%, Pro versus Ala). We found no
modifications of SAP97 and ADAM10 levels in total homogenate,
suggesting that the observed uncoupling can be ascribed to a
decreased association rather than to changes in levels of these
proteins (Fig. 1C; ADAM10: n= 4; P40.05; +12.6 4.9%;
SAP97: n= 4; P40.05; +9.7 10.7%, Pro versus Ala).
To validate the relevance of the ADAM10/SAP97 complex for
Alzheimer’s disease pathogenesis, we performed a biochemical
analysis of hippocampi from Alzheimer’s disease patients at
Braak level 4 (Braak and Braak, 1991) and of age-matched healthy
controls. Braak level 4 corresponds to initial stages of sporadic
disease, and the hippocampus was analysed as a strongly affected
area. Total brain homogenates from hippocampi of healthy con-
trols and patients with Alzheimer’s disease were
immunoprecipitated with anti-ADAM10 antibody, and SAP97
co-immunoprecipitation was evaluated. We revealed a decrease
of the ADAM10/SAP97 immunocomplex in Alzheimer’s disease
patients compared with healthy controls (Fig. 1D; n= 6;
P= 0.001, 33.7 4.9%, Alzheimer’s disease versus healthy con-
trols), suggesting uncoupling of the ADAM10/SAP97 complex as
an early event in Alzheimer’s disease pathogenesis. No differences
were detected between healthy controls and patients with
Alzheimer’s disease in SAP97 and ADAM10 levels in total brain
homogenates (SAP97: n= 6, P40.05; +31.4 35.1%; ADAM10:
n= 6, P40.05, 7.7 11.7%, Alzheimer’s disease versus healthy
controls), underlying that the ADAM10/SAP97 complex is not
reduced in Alzheimer’s disease due to lower expression of the
two proteins.
Pro peptide is specific in disrupting
ADAM10/SAP97 complex
We investigated Pro peptide specificity in disrupting the ADAM10/
SAP97 complex, without influencing other protein–protein
interactions.
First, the capability of SAP97 SH3 domain to bind other partners
in the presence of Pro was evaluated. Cell-based studies suggest
that Akap79/150, a signalling scaffold, is recruited to AMPA
(-amino-3-hydroxy-5-methyl-4-isoxazole-propionic acid) recep-
tors through interaction with SH3/GK domains of SAP97
(Colledge et al., 2000). We performed co-immunoprecipitation
experiments between SAP97 and Akap79/150. No alterations
were found in Akap79/150/SAP97 association (Fig. 2A; n= 4,
P40.05, 8.7 31.3%, Pro versus Ala). SAP97 has been recog-
nized as a cargo element responsible for synaptic trafficking of key
elements of the glutamatergic synapse, i.e. the NR2A subunit
of the glutamate N-methyl-D-aspartic acid (NMDA) receptor
(Gardoni et al., 2003) and the GluR1 subunit of the glutamate
3326 | Brain 2010: 133; 3323–3335 R. Epis et al.






AMPA receptor (Sans et al., 2001). Pro specificity was assessed by
analysing the binding of these partners to SAP97 by
co-immunoprecipitation between SAP97 and NR2A, as well as
between SAP97 and GluR1. No alterations were found in either
SAP97/NR2A association (Fig. 2B; n= 4, P40.05, +6.3 20.4%,
Pro versus Ala) or in the SAP97/GluR1 immunocomplex (Fig. 2C;
n= 4, P40.05, 21.2 9.4, Pro versus Ala) after treatment.
Moreover, the Pro peptide did not interfere with binding of
other synaptic SH3 to Pro-rich domains, as assessed by
co-immunoprecipitation of PYK2 and PSD-95 (Fig. 2D; n= 4;
P40.05, +50.4 51.2, Pro versus Ala; Seabold et al., 2003).
Altogether, these data indicate that Pro is specific for its capability
to interfere with the ADAM10/SAP97 complex.
Treatment with Pro alters ADAM10
localization and generates the
characteristic features of Alzheimer’s
disease: amyloidogenesis and tau
hyperphosphorylation
SAP97 is necessary to drive ADAM10 to the plasma membrane
(Marcello et al., 2007). We asked whether the reduction in
ADAM10/SAP97 association, obtained through Pro peptide treat-
ment, could induce a modification in ADAM10 localization.
Western blot analysis performed on TIF—a fraction enriched in
proteins of the postsynaptic density (Gardoni et al., 2001)—
revealed a statistically significant reduction of ADAM10 levels in
mice treated with Pro compared with mice treated with Ala (Fig.
3A; n= 4; P= 0.006, 16.7 2.2%, Pro versus Ala). No changes
were observed in SAP97 immunoreactivity in the TIF (Fig. 3A;
n= 4, P40.05, 10.4 5.1%, Pro versus Ala).
Since ADAM10 is active at the plasma membrane (Lammich
et al., 1999), we supposed that the reduction of ADAM10 in
the postsynaptic compartment could be paralleled by a decrease
Figure 1 ADAM10/SAP97 association is reduced after 2 weeks of treatment with Pro peptide and in patients with Alzheimer’s disease.
(A) Schematic representation of SAP97, ADAM10 and Pro peptide. (B) C57BL/6 mice were treated for 2 weeks with Pro or Ala peptides and
total brain homogenates were co-immunoprecipitated with anti-ADAM10 antibody. SAP97 presence was evaluated in the immunocomplex.
Treatment with Pro peptide decreases the association of the two proteins (P= 0.005). (C) Western blot of homogenate from Pro- and
Ala-treated mice performed with anti-ADAM10 and anti-SAP97 antibodies. No changes were detectable in ADAM10 and SAP97 levels. All
data were normalized to actin. (D) Homogenate from hippocampi of healthy controls (HC) and patients with Alzheimer’s disease (AD) was
immunoprecipitated with anti-ADAM10 antibody and SAP97 co-precipitation was evaluated. ADAM10/SAP97 association is reduced in
Alzheimer’s disease patients compared with healthy controls (P= 0.001). For all experiments, quantitative analysis of immunostaining is
shown as percentage of control (Ala or healthy controls) in the same experiment. i.p. = immunoprecipitation; WB = western blot.
Figure 2 Pro peptide treatment does not interfere with
protein–protein complexes other than ADAM10/SAP97.
(A) C57BL/6 mice were treated for 2 weeks with Pro or Ala
peptides and total brain homogenates were
co-immunoprecipitated with anti-Akap79/150 antibody. SAP97
presence was evaluated in the immunocomplex. The association
is not altered by treatment. (B) C57BL/6 mice were treated for
2 weeks with Pro or Ala peptides and total brain homogenates
were co-immunoprecipitated with anti-SAP97 antibody. NR2A
presence was evaluated in the immunocomplex. The association
is not altered by treatment. (C) C57BL/6 mice were treated for
2 weeks with Pro or Ala peptides and total brain homogenates
were co-immunoprecipitated with anti-GluR1 antibody. SAP97
presence was evaluated in the immunocomplex. The association
is not altered by treatment. (D) C57BL/6 mice were treated for
2 weeks with Pro or Ala peptides and total brain homogenates
were co-immunoprecipitated with anti-PYK2 antibody. PSD-95
presence was evaluated in the immunocomplex. The association
is not altered by treatment. For all experiments, quantitative
analysis of immunostaining is shown as percentage of Ala
treatment in the same experiment. i.p. = immunoprecipitation;
WB = western blot.
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in its activity towards its synaptic substrates. sAPP release, deriv-
ing from ADAM10 cleavage on amyloid precursor protein, was
decreased in Pro-treated compared with Ala-treated mice (Fig.
3B; n= 4, P= 0.043, 22.7 4.6%, Pro versus Ala), whereas we
observed no alterations in the processing of N-cadherin, another
ADAM10 synaptic substrate (Reiss et al., 2005; Fig. 3C; n= 4;
homogenate: 9.1 19.6%; TIF: +5.7 10.5%; overall P40.05,
Pro versus Ala).
To exclude compensatory upregulation of other metallopro-
teases after 2 weeks of treatment, levels of matrix metallopepti-
dase 9 (MMP-9) and its gelatinolytic activity were analysed. No
alterations were found in MMP-9 total brain homogenate levels
or in its gelatinolytic activity (Supplementary Fig. 2A; n= 4; hom-
ogenate: +12.2 5.6%, P40.05; Supplementary Fig. 2B; n= 4;
zymography: 8.7 6.5%, P40.05; Pro versus Ala).
Altered amyloid precursor protein metabolism induced by Pro
peptide treatment was further investigated. We measured amyloid
precursor protein CTFs: CTF83 for -secretase and CTF99 for
b-secretase cleavage, in TIF. The CTF83/CTF99 ratio was reduced
in mice treated with Pro compared with mice treated with Ala,
indicating a shift of amyloid precursor protein metabolism towards
amyloidogenesis in Pro-treated mice (Fig. 4A; n= 4, P= 0.03,
28.6 5.7%, Pro versus Ala). The shift of amyloid precursor
protein metabolism towards Ab production was further confirmed
by the raise in Ab1–42 production detected by ELISA in total brain
homogenate of mice treated with Pro if compared with
Ala-treated mice (Fig. 4B, n= 4; P= 0.02; +16.8 4.6%, Pro
versus Ala).
An initiating factor in Alzheimer’s disease pathogenesis occurs
when soluble, monomeric Ab undergoes a conformational change
and converts into oligomeric forms (Klein et al., 2001). Although
murine Ab is less prone to aggregation than human Ab, we de-
tected low-n Ab oligomers in formic acid soluble extracts obtained
by sequential centrifugation of brain homogenates (Lesne et al.,
2006). An antibody raised against the N-terminus of Ab, AB2072,
revealed an increase of an oligomeric aggregate at 16 kDa, a
molecular mass corresponding to tetramers (Fig. 4C; n= 4,
P= 0.0005, +18.3 1.8%, Pro versus Ala) in Pro-treated mice.
The detection of this band with AB2072 and 4G8, recognizing
Ab mid-domain, excludes the possibility that it represents degrad-
ation products of soluble amyloid precursor protein. The band was
not recognized by antibodies for epitopes at the C-terminus or the
N-terminus of amyloid precursor protein, amyloid precursor pro-
tein C-Term and 22C11, respectively, indicating it was neither
one of the amyloid precursor protein CTFs nor amyloid precursor
protein cleavage-end products (Supplementary Fig. 3A and
Supplementary Methods). As revealed by Congo Red staining,
we detected no plaques in Pro- and Ala-treated mice (Fig. 4D),
suggesting that we are mimicking the early stages of Alzheimer’s
disease (Oddo et al., 2003).
Since Ab production triggers the development of other
Alzheimer’s disease hallmarks, such as neurofibrillary tangles
(Oddo et al., 2003), we evaluated the presence of tau hyperphos-
phorylation. Tau phosphorylation in serine202–205 was increased
in mice treated with Pro peptide (Fig. 4E; n= 4, P= 0.038,
+53.2 15.0%, Pro versus Ala). This was corroborated by immu-
nohistochemical analysis showing tau hyperphosphorylation in
soma, axons and dendrites of neurons in the cerebral cortex of
Pro-treated mice compared with Ala-treated ones (Fig. 4F).
Tau-C3 antibody is specific for tau cleaved at aspartic acid421,
which represents a further stage of neurofibrillary tangle evolution
in Alzheimer’s disease (Gamblin et al., 2003). Tau-C3 staining re-
vealed no signal in both groups (Supplementary Fig. 3B).
Effects of Pro peptide treatment on
spine morphology and on molecular
composition of the excitatory
glutamatergic synapse
Synaptic dysfunction appears as an early event in disease
pathogenesis with synapse loss evident in patients at early
stages of Alzheimer’s disease and with mild cognitive impairment
Figure 3 Pro treatment alters ADAM10 localization and activity on amyloid precursor protein. (A) Western blot of TIF from Pro- and
Ala-treated mice performed with anti-ADAM10 and anti-SAP97 antibodies. Pro treatment reduced ADAM10 levels (P= 0.006) without
modifying SAP97 levels. All data were normalized to actin. (B) Western blot performed on the soluble fraction S2 of mice treated with
Pro or Ala peptides. sAPP/sAPPtot ratio is reduced in mice treated with Pro peptide (P= 0.043). (C) Western blot performed on total
brain homogenate and TIF fraction of Pro- and Ala-treated mice to reveal N-cadherin full-length (fl) and C-terminal fragment (Ctf).
N-cadherin fl/Ctf ratio was not altered by the treatment with Pro peptide. For all experiments, quantitative analysis of immunostaining is
shown as percentage of Ala treatment in the same experiment.
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(Scheff et al., 2007). We evaluated potential alterations of synap-
tic morphology associated with the observed shift of amyloid pre-
cursor protein metabolism towards amyloidogenesis. Analysis of
dendritic spines was performed using DyOlistic fluorescent label-
ling (Gan et al., 2000). We measured density (N/10mm), area,
neck length and head width of dendritic spines in the hippocam-
pus and cortex. Statistical analysis showed no differences in all
parameters between animals treated with Pro and Ala peptides,
indicating that we are analysing the early stages preceding spine
loss and degeneration [Fig. 5A; (i) cortex Ala: n= 33, area
0.384 0.009 mm2, length 1.29 0.02mm, width 0.53 0.01mm,
spines/10 mm 10.67 0.42; Pro: n= 33, area 0.348 0.01mm2,
length 1.30 0.01 mm, width 0.557 0.01mm, spines/10 mm
10.53 0.44; overall P40.05; Fig. 5B; (ii) hippocampus
Ala: n= 33; area 0.312 0.009 mm2, length 0.884 0.01mm,
width 0.483 0.008 mm, spines/10 mm 12.31 0.573; Pro:
n= 33, area 0.307 0.008mm2, length 0.84 0.01mm, width
0.474 0.007 mm, spines/10 mm 12.10 0.48; overall P40.05].
To characterize molecular events occurring prior to synaptic loss,
we evaluated biochemically the composition of glutamatergic
postsynaptic density. No alterations in PSD-95 (Fig. 6A;
n= 4; homogenate: +12.7 6.1%; TIF: +1.2 6.6%; overall
P40.05, Pro versus Ala) and -CaMKII (Fig. 6A; n= 4;
homogenate: 1.1 2.7%; TIF: +30.2 18.9%; overall P40.05,
Pro versus Ala) levels were found, confirming no major modifications
of postsynaptic density organization in early stages of Ab formation.
We detected no significant alterations in GluR1 (Fig. 6A; n= 4;
homogenate: +18.6 26.0%; TIF: +20.3 23.1%; overall
P40.05, Pro versus Ala) and GluR2 (Fig. 6A; n= 4; homogenate:
+0.9 10.9%; TIF: +25.3 7.2%; overall P40.05, Pro versus Ala)
AMPA receptor subunit levels in total homogenate and TIF in
Pro-treated animals compared with Ala-treated ones. NR1, the
NMDA receptor constitutive subunit, was unaltered (Fig. 6B; n= 4;
homogenate: +19.4 14.7%; TIF: +20.2 8.0%; overall P40.05,
Pro versus Ala) as was NR2B (Fig. 6B; n= 4; homogenate:
2.6 5.4%; TIF: +7.4 7.8%; overall P40.05, Pro versus Ala),
but a specific reduction of NR2A subunit in TIF was observed
(Fig. 6B; n= 4; homogenate: +17.1 8.4%, P40.05; TIF:
27.4 2.8%, P= 0.002, Pro versus Ala).
This modification of the molecular composition of glutamatergic
postsynaptic density in Pro-treated mice temporally follows Ab
production. We evaluated the ADAM10/SAP97 immunocomplex
(1 day: P= 0.008, 32.4 3.9%; 7 days: P= 0.003, 25.4
2.4%, Pro versus Ala), ADAM10 in TIF (1 day: P= 0.04,
21.3 2.7%; 7 days: P= 0.019, 17.5 4.2%, Pro versus Ala)
as well as amyloid precursor protein metabolites at Days 1 and 7
Figure 4 Pro treatment induces Alzheimer’s pathological hallmarks. (A) Western blot performed on the TIF of Pro- and Ala-treated mice
to reveal amyloid precursor protein CTFs. CTF83/CTF99 ratio is decreased in mice treated with Pro peptide (P= 0.03). (B) Quantification
of Ab1-42 production in mice treated with Pro compared with Ala. Ab1-42 production is increased after Pro treatment (P= 0.02).
(C) Western blot performed on the formic acid soluble fraction S4 of Pro- and Ala-treated mice to reveal Ab oligomers. A 16 kDa band
(at theoretical apparent molecular mass of tetramers) is increased after Pro treatment (P= 0.0005). (D) Representative images of Congo
Red staining showing no senile plaques in Pro- and Ala-treated mice (scale bar = 500 mm and 200mm). (E) Western blot performed on
homogenate from mice treated with Pro or Ala peptides. Tau phosphorylation is increased in Pro-treated mice (P= 0.038). Data were
normalized to actin. (F) Representative images of phosphorylated-tau (P-Tau) staining showing increased phosphorylation in Pro-treated
mice (scale bar = 100mm). For all experiments, quantitative analysis of immunostaining is shown as percentage of Ala treatment in the
same experiment.
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Figure 6 Effects of Pro treatment on the glutamatergic synapse. (A) Western blot of homogenate (Homo) and TIF from Pro- and
Ala-treated mice performed with anti-GluR1, anti-GluR2, anti-PSD-95 and anti--CaMKII antibodies. (B) Western blot of homogenate
and TIF from Pro- and Ala-treated mice performed with anti-NR1, anti-NR2A and anti-NR2B antibodies. NR2A is decreased in the TIF
(P= 0.002). (C) Western blot analysis of the TIF and soluble fraction S2 of mice treated for 1 or 7 days with Pro or Ala. The CTF83/CTF99
ratio is reduced in mice treated with Pro peptide for 1 day (P= 0.01) and 7 days (P= 0.035). sAPP/sAPPtot ratio is reduced in mice treated
with Pro peptide for 1 day (P= 0.02) and 7 days (P= 0.015). NR2A is reduced in the TIF after 7 days of treatment with Pro (P= 0.01) but
not after 1 day. All data were normalized to actin. For all experiments, quantitative analysis of immunostaining is shown as percentage of
Ala treatment in the same experiment.
Figure 5 Effects of Pro treatment on spine density and morphology. Representative images of cortical layer I (A) and hippocampal CA1
apical (B) spines from Pro- and Ala-treated mice. Statistical analysis of spine density, neck length, head width and area revealed no
modifications in both areas (scale bar = 5 mm).
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of treatment. sAPP/total sAPP and CTF83/CTF99 ratios were
shifted towards amyloidogenesis after both 1 and 7 days of treat-
ment with the Pro peptide (Fig. 6C; 1 day: n= 4; sAPPalpha/tot:
P= 0.02, 39.7 5.2%; CTF83/99: P= 0.01, 34.3 7.9%, Pro
versus Ala; 7 days: n= 4; sAPPalpha/tot: P= 0.015, 10.1 2.3%;
CTF83/99: P= 0.035, 45.8 15.2%, Pro versus Ala). In parallel,
NR2A levels in TIF were measured. After 7 days, but not 1 day, of
Pro peptide treatment, NR2A decreased in postsynaptic density
(Fig. 6C; n= 4, 1 day: P40.05, +9.1 14.8%; 7 days: P= 0.01,
17.8 3.5%, Pro versus Ala).
These results suggest that increases in Ab production precede
alterations of excitatory synapses.
Functional deficits: electrophysiological
and behavioural consequences of Pro
peptide treatment
We then evaluated activity-dependent synaptic plasticity. We tested
long-term potentiation in the CA1 region of acute hippocampal slices
obtained from mice treated with either the Pro or Ala peptide for
14 days. When potentiation of CA3–CA1 synapses was induced by
high-frequency stimulation, no effects of peptide treatment were
found on the magnitude of long-term potentiation measured
50–60 min after high-frequency stimulation. However, the max-
imum potentiation of the synaptic response immediately following
high-frequency stimulation was significantly reduced in Pro-treated
mice (Fig. 7A; P50.02, ANOVA, Pro: 278.8 37.89%; Ala:
418.70 29.27%). This reduction of synaptic plasticity induced by
the Pro peptide was statistically significant up to 10 min after
high-frequency stimulation, a period in which enhancements of syn-
aptic responses can be attributable to the buildup and decay of
post-tetanic potentiation (Zucker and Regehr, 2002), a form of
short-term synaptic plasticity.
To assess behavioural dysfunctions paralleling the alterations in
synaptic organization and function, we performed a Novel Object
Recognition test on animals treated with Pro or Ala for 2 weeks.
Treated mice were unable to distinguish new objects from known
ones, with no significant difference in the percentage of time
spent investigating the two objects. Discrimination index between
novel and familiar objects revealed a prominent effect of treat-
ment with the Pro peptide. Post hoc analysis found a significant
inability to discriminate between the two objects in Pro-treated
mice [Fig.7B; discrimination index, Ala: 0.26; Pro: 0.01; saline:
0.3; ANOVA (Pro/Ala) P= 0.04]. To assess whether administration
of the peptides influenced the mobility of mice, the number of
total movements in 5 min was determined and no significant dif-
ferences were found between the groups [Fig. 7C; number of
movements/5 min, Ala: 139.8 8.5; Pro: 156.6 13.7; saline:
157.8 14.0; ANOVA (Pro/Ala) P40.05].
Discussion
Development of adequate animal models mimicking all stages of
Alzheimer’s disease progression and merging convergent pathways
of pathogenesis still represents a need for research on Alzheimer’s
disease. Available mouse models have been generated on the basis
of identified human mutations (Goate et al., 1991; Scheuner
et al., 1996). Although informative for the understanding of
molecular pathogenesis of the disease, these models present a
number of weaknesses (Epis et al., 2010; Morrissette et al.,
2009). In transgenic models, mutated proteins are chronically
overexpressed and exposure to Ab overproduction starts before
Figure 7 Effects of Pro-treatment on glutamatergic synapse
function. (A) A reduction in post-tetanic potentiation induced by
high-frequency stimulation (HFS; 4 100 Hz, 1 s, 30 s apart)
was observed in Pro-treated mice (open circles, n= 8 slices from
n= 3 mice) compared with Ala-treated (full circles, n= 8 slices
from n= 3 mice; P50.01, ANOVA). Long-term potentiation
measured 50–60 min after HFS was similar in the presence of
either peptide. Insets illustrating averaged extracellular field
excitatory postsynaptic potentials from three consecutive traces
taken before (1) and at different times after HFS (2 and 3)
are shown above summary data. Error bars indicate SEM.
(B) Quantification of the discrimination index of mice treated
with Pro or Ala peptides in the novel object recognition test.
Mice treated with Pro peptide show a reduced discrimination
index compared with those treated with Ala peptide (P= 0.042,
ANOVA) and with saline-treated mice (P= 0.021, ANOVA).
(C) Quantification of the number of movements in 5 min in mice
treated with Pro or Ala peptides in the Novel Object Recognition
test. All behavioural data are expressed as means  SEM (n= 9
per group).
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the common clinical onset of Alzheimer’s disease. The genetic
strains, the mutations and the different transcriptional promoters
used to drive their expression, as well as other factors that are not
completely known, produce different amounts of Ab, forming po-
tentially different oligomeric forms, which may induce high vari-
ability and different outcomes across transgenic mouse models
(Epis et al., 2010; Gerlai, 1996; Morrissette et al., 2009).
Here, we propose a different approach to investigating the con-
sequences of Ab increase in an innovative, non-transgenic animal
model of early Alzheimer’s disease.
Our strategy is based on interference with the ADAM10/SAP97
protein complex in adult mice. We have already reported the
interaction with the PSD-MAGUK protein SAP97 as pivotal for
ADAM10 trafficking to the postsynaptic membrane and for its
enzymatic non-amyloidogenic cleavage on amyloid precursor pro-
tein (Marcello et al., 2007). The relevance of the ADAM10/SAP97
complex in early stages of disease is strengthened by our analysis
of the hippocampus of patients at Braak level 4 of Alzheimer’s
disease, where we observed a clear reduction in ADAM10/
SAP97 co-immunoprecipitation. These results suggest that the
defect of interaction between the two proteins is relevant for
human pathology.
Through administration of a cell-permeable peptide, Pro, for
2 weeks, we were able to reproduce ADAM10/SAP97 uncoupling
in vivo in rodent brains. In Pro peptide, the short Tat sequence (11
amino acids) (Aarts et al., 2002) is fused to the 32 amino acid
sequence of the proline-rich domains of ADAM10, responsible for
the direct binding to the SH3 domain of SAP97 (Marcello et al.,
2007). The peptide does not interfere with other protein com-
plexes, implying that reported functional and behavioural modifi-
cations are not related to off-target effects.
Treatment of mice for 2 weeks with Pro peptide reduces
ADAM10/SAP97 association and, consequently, ADAM10 local-
ization to the postsynaptic membrane.
Specificity of the effects obtained after peptide treatment re-
mains high with regard to the large number of ADAM10 sub-
strates already described in the literature. This could be ascribed
to either: (i) not all ADAM10 substrates are neuronally expressed;
or (ii) our model is fully based on the uncoupling of the ADAM10/
SAP97 complex in a very confined structure, the glutamatergic
synapse, where both proteins are located. Again, among neuronal
ADAM10 substrates, not all have spine localization.
Pro peptide treatment influences amyloid precursor protein me-
tabolism, reducing -secretase-mediated processing without af-
fecting the processing of other synaptic, but developmentally
relevant substrates, such as N-cadherin. The molecular rationale
supporting the lack of ADAM10 cleavage of N-cadherin in the
mature spine is at present not completely clear. Nonetheless, we
can speculate that either clusterization of the enzyme or different
accessibility of the substrates in mature spines compared with
developmental stages could be relevant.
Importantly, there are no specific chemical inhibitors for basal
ADAM10/-secretase activity (Ludwig et al., 2005). Pro peptide
could therefore represent an appropriate tool to study the physio-
logical role of ADAM10.
Exposing mice to Pro peptide for 2 weeks affects amyloid pre-
cursor protein metabolism, increasing amyloid precursor protein
amyloidogenic cleavage with a modest but significant raise of
Ab release and of low-n Ab aggregate production. This subtle
increase in Ab appears particularly promising when compared
with data collected from studies in engineered animal models,
where accumulation of soluble Ab is normally reported in older
animals, i.e. 9–13 months of age (Holcomb et al., 1998; Oddo
et al., 2003a). Similarly, even in triple transgenic mice, Ab oligo-
mers can be revealed after 13 months of age (Oddo et al., 2003b,
2006). Notably, in our conditions, the slight increase of both sol-
uble Ab and its low-n aggregates is evident after just 2 weeks of
treatment. Although the low aggregation capability of rodent Ab
can be considered a limitation, ADAM10/SAP97 uncoupled ani-
mals still appear as a promising model to study early phases of
Alzheimer’s disease.
From a pathological point of view, hallmarks of Alzheimer’s dis-
ease include extracellular amyloid plaques as well as intracellular
neurofibrillary tangles (Selkoe, 2001). The latter trait is character-
istic of human Alzheimer’s disease but is not always present in
amyloid models (Morrissette et al., 2009), which in most cases
do not even show tau hyperphosphorylation. For instance,
mutant presenilin-1 mice crossed with mutant amyloid precursor
protein mice fail to develop detectable neurofibrillary tangles
(Holcomb et al., 1998) and also in triple transgenic mice, lesions
accumulate in an age-dependent fashion (Oddo et al., 2003a). In
ADAM10/SAP97 uncoupled mice, tau hyperphosphorylation, but
not neurofibrillary tangles, was already evident after 2 weeks of
treatment with Pro peptide, further supporting our hypothesis that
these mice mimic early phases of pathology.
However, rather than deposition of amyloid plaques or neuro-
fibrillary tangles, the most robust correlation in the staging of de-
mentia and early Alzheimer’s disease is the magnitude of synapse
loss (Terry et al., 1991; Scheff et al., 2007). Spine loss and alter-
ations in morphology have been linked to Ab and its oligomeric
aggregates in in vivo and in vitro studies (Lacor et al., 2004;
Shankar et al., 2008; Wei et al.), suggesting a convergence be-
tween the main causes of Alzheimer’s disease pathogenesis: amyl-
oid cascade and synaptic alterations. In ADAM10/SAP97
uncoupled mice, we failed to adversely affect spine number and
to alter spine morphology, probably because of the limited time of
in vivo exposure to Ab and its aggregates. The reasons for spine
alterations in Alzheimer’s disease remain controversial. Data emer-
ging from a variety of transgenic mouse lines have pointed out a
role for both low- and high-number oligomers (Jacobsen et al.,
2006). Their mechanism of action remains elusive, mostly because
the vast majority of studies on the effects of Ab oligomers on
spine morphology have been carried out in vitro using in vivo-
produced oligomers. A better knowledge of the mechanisms
underlying spine deterioration in patients with Alzheimer’s disease,
which might involve effects of Ab on cytoskeletal (Alvarez and
Sabatini, 2007) and mitochondrial dysfunction (Hauptmann
et al., 2009), would be crucial for speculations on the reasons
for the lack of spine alterations in our model. Studies with
longer exposure to the Pro peptide might be helpful to dissect
structural effects of ADAM10/SAP97 uncoupling.
Nevertheless, in ADAM10/SAP97 uncoupled mice, synaptic suf-
ferance occurs prior to anatomical changes and is evident as a
reorganization of the molecular composition of excitatory
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glutamatergic synapse, with a selective reduction of the NR2A
NMDA subunit. Recently, an effect of Ab oligomers on NMDA
receptor subunits has been reported, revealing an effect on NR2B
trafficking and internalization (Snyder et al., 2005; Lacor et al.,
2007). Our current findings on NR2A and spine morphology seem
apparently contradictory, when compared with recent literature.
This could be due to experimental discrepancies among studies,
including different Ab species, different stages of pathology or
mice development at exposure and different concentrations and/
or oligomerization state of Ab (Billings et al., 2005). The site of
action of Ab should also be considered, since intracellular and
extracellular pools of Ab may differently influence synaptic func-
tion, and the net outcome may depend on their dynamic relation-
ship (Venkitaramani et al., 2007). However, in agreement with
previous studies (Cleary et al., 2005), in our experimental condi-
tions, NMDA subunit modifications at synaptic sites follow Ab
formation and accumulation, suggesting Ab formation as the start-
ing event of pathogenesis.
In our model, we described activity-dependent alterations of
synaptic plasticity as well as an initial cognitive deficit in the
Novel Object Recognition test, paralleling NR2A reduction.
Interestingly, recent reports showed that long-term potentiation
impairment in transgenic mice models of Alzheimer’s disease de-
pends on the age of the animals and, presumably, on Alzheimer’s
disease stage. For example, studies in ArcAb mice (where a form
of Ab more prone to yielding Ab oligomers is expressed) revealed
that long-term potentiation is impaired in mice of 3.5 and
7.5 months of age, but not in those of 1 month, probably because
at this age, Ab accumulation is not yet detectable (Knobloch et al.,
2007). In light of these previous data, lack of differences in hip-
pocampal long-term potentiation in our model could be correlated
to the early stage of Alzheimer’s disease pathology revealed
by our biochemical and morphological results. On the other
hand, alterations in short-term synaptic plasticity found in our
model have been documented in other Alzheimer’s disease
models. For example, double transgenic mice overexpressing the
mutated form of amyloid precursor protein (APPK670N, M671L)
and presenilin-1 (PS1M146V) exhibit enhanced synaptic fatigue,
a form of short-term synaptic plasticity, at the Schaffer
collateral-CA1 synapse (Zhang et al., 2005). Intriguingly, because
short-term synaptic changes are relevant in cognitive processes
such as learning and memory, it is conceivable that alterations in
the synaptic plasticity shown by our Alzheimer’s disease model
could be one leading cause of the impaired behavioural perform-
ances of these animals. Indeed, Pro peptide treated mice showed a
marked impairment in the Novel Object Recognition test, which
measures recognition memory and is heavily altered in Alzheimer’s
disease. This test relies on spontaneous animal behaviour without
the need for stressor elements. Pro peptide treatment impairs
memory consolidation within 24 h and rapidly interferes with the
synaptic activity necessary for the stabilization of new memories.
In conclusion, our model can be used to study pathogenic con-
sequences of a specific pathway of Alzheimer’s disease pathogen-
esis, namely ADAM10/SAP97 disruption. Pro peptide treated
animals manifest all characteristics of the early stages of
Alzheimer’s disease, i.e. increased Ab production and presence
of low-n aggregates, hyperphosphorylated tau and clear synaptic
dysfunction as reflected by aberrant composition of NMDA recep-
tors, altered activity-dependent plasticity and impaired behavioural
performance. These manifestations occur prior to synapse loss and
spine modifications and before the appearance of full pathological
hallmarks, i.e. amyloid plaques and neurofibrillary tangles (Selkoe,
2008), highlighting the relevance of our model in studying the
early stages of Alzheimer’s disease.
Pro peptide strategy offers the unprecedented possibility to
interfere with endogenous amyloid precursor protein processing
in adult mice by neither overexpressing proteins derived from in-
herited forms of the disease nor altering developmental processes.
Moreover, it can be useful to study the convergence as well as the
temporal correlation of multiple neuropathological pathways, such
as Ab production and synaptic dysfunction and, eventually, to
investigate new therapeutic strategies.
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